NLS Pharmaceutics (NLSP) Secures a Bridge Loan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
November 16, 2023 8:01 AM ESTNLS has executed a non-binding term sheet for licensing of NLS intellectual propertyNLS has secured an additional bridge loan through insiders to extend cash runwayNLS has implemented significant internal cost reductions
ZURICH, SWITZERLAND / ACCESSWIRE / November 16, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it is conducting an ongoing process to explore strategic alternatives... More
